Literature DB >> 11832957

Medical need, scientific opportunity and the drive for antimalarial drugs.

Robert G Ridley1.   

Abstract

Continued and sustainable improvements in antimalarial medicines through focused research and development are essential for the world's future ability to treat and control malaria. Unfortunately, malaria is a disease of poverty, and despite a wealth of scientific knowledge there is insufficient market incentive to generate the competitive, business-driven industrial antimalarial drug research and development that is normally needed to deliver new products. Mechanisms of partnering with industry have been established to overcome this obstacle and to open up and build on scientific opportunities for improved chemotherapy in the future.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11832957     DOI： 10.1038/415686a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  153 in total

Review 1.  Chemotherapeutic hope on the horizon for Plasmodium vivax malaria?

Authors:  Robert G Ridley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships.

Authors:  Robert G Ridley
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

Review 3.  Malaria.

Authors:  Christopher J M Whitty; Mark Rowland; Frances Sanderson; Theonest K Mutabingwa
Journal:  BMJ       Date:  2002-11-23

4.  The role of two novel regulatory sites in the activation of the cGMP-dependent protein kinase from Plasmodium falciparum.

Authors:  Wensheng Deng; Asha Parbhu-Patel; David J Meyer; David A Baker
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

Review 5.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Molecular dynamics investigation of psalmopeotoxin I. Probing the relationship between 3D structure, anti-malarial activity and thermal stability.

Authors:  Matthew Paul Gleeson; Songpon Deechongkit; Somsak Ruchirawat
Journal:  J Mol Model       Date:  2010-06-12       Impact factor: 1.810

7.  Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.

Authors:  Laurent-Olivier Roy; Marie-Belle Poirier; David Fortin
Journal:  Invest New Drugs       Date:  2015-08-15       Impact factor: 3.850

8.  Comparative characterization of hexose transporters of Plasmodium knowlesi, Plasmodium yoelii and Toxoplasma gondii highlights functional differences within the apicomplexan family.

Authors:  Thierry Joët; Lennart Holterman; Timothy T Stedman; Clemens H M Kocken; Annemarie Van Der Wel; Alan W Thomas; Sanjeev Krishna
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

9.  A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa.

Authors:  B N Thomas; B Donvito; I Cockburn; T Fandeur; J A Rowe; J H M Cohen; J M Moulds
Journal:  Genes Immun       Date:  2005-02       Impact factor: 2.676

10.  Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.

Authors:  Koushi Hidaka; Tooru Kimura; Adam J Ruben; Tsuyoshi Uemura; Mami Kamiya; Aiko Kiso; Tetsuya Okamoto; Yumi Tsuchiya; Yoshio Hayashi; Ernesto Freire; Yoshiaki Kiso
Journal:  Bioorg Med Chem       Date:  2008-10-10       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.